Radiation Injuries Clinical Trial
Official title:
The Effect of Thalidomide in Radiation-induced Brain Injury(RI): a Phase II Clinical Trial
Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects
and side effects of thalidomide in radiation-induced brain injury.
Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University /
Yameitang.
Primary outcome measure: The primary endpoint is the brain injury remission at week 15. In
brief, the brain lesion will be evaluated by using brain MRI scan before and after
thalidomide regimen. The clinical efficacy is defined as ≥ 25% reduction in brain edema
volume on FLAIR images at week 15, as compared with that before thalidomide usage.
Status | Recruiting |
Enrollment | 58 |
Est. completion date | July 30, 2020 |
Est. primary completion date | January 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years and older |
Eligibility |
Inclusion Criteria - Prior irradiation >/= 12 months prior to study entry. - Radiographic evidence to support the diagnosis of radiation-induced brain injury without tumor recurrence. - Age>/= 35 years. - Contraindication to glucocorticoids and bevacizumab treatment due to history or high risk of severe adverse effects, or non-effective response to glucocorticoids and bevacizumab treatment in 12 months prior to study entry. - Estimated life expectancy must be greater than 12 months. - Routine laboratory studies: bilirubin </=1.0 * upper limits of normal (ULN); aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT)< 1.0 * ULN; creatinine <1.0 * ULN; white-cell count >/= 4,000 per cubic millimeter; neutrophils count >/=1500 per cubic millimeter platelets >/= 100,000 per cubic millimeter; Hb >/=110 gram per millilitres; PT, APTT, INR in a normal range. - Ability to understand and willingness to sign a written informed consent document, or constant caregivers who well understand and willingness to sign a written informed consent document. Exclusion Criteria - Evidence of tumor metastasis, recurrence, or invasion; - Current usage of bevacizumab; - Current usage of glucocorticoids; - Evidence of very high intracranial pressure that suggests brain hernia and need surgery; - History of psychiatric diseases before radiotherapy; - History of seizures; - History of arteriosclerotic cardiovascular diseases (ASCVD), e.g. stroke, myocardial infaction, unstable angina, within 6 months; - New York Heart Association Grade II or greater congestive heart failure; - Serious and inadequately controlled cardiac arrhythmia; - Significant vascular disease, e.g. moderate or severe carotid stenosis, aortic aneurysm, history of aortic dissection; - Severe infection; - History of allergy to relevant drugs; - Pregnancy, lactation, or fertility program in the following 12 months; - History or current diagnosis of peripheral nerve disease; - Abnormal in liver and renal function; - Active tuberculosis; - Transplanted organs; - Human immunodeficiency virus; - Participation in other experimental studies. |
Country | Name | City | State |
---|---|---|---|
China | Cancer canter of Sun Yat-sen University | Guangzhou | Guangdong |
China | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University | Guangzhou | Guangdong |
China | Guangzhou Huiai Hospital | Guanzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the brain injury remission | The brain injury remission is defined as = 25% reduction in brain edema volume on FLAIR images at week 15, as compared with that before thalidomide usage | Week 15 | |
Secondary | improvement of quality of life | the difference value of WHO-QOL scale before and after thalidomide regimen | Week 15 | |
Secondary | improvement of neurological function | the difference value of LENT/SOMA scales before and after thalidomide regimen | Week 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Completed |
NCT02985164 -
Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography
|
Phase 3 | |
Recruiting |
NCT04152681 -
Effect and Safety of Apatinib on Radiation-Induced Brain Injury
|
Phase 2 | |
Recruiting |
NCT04818099 -
Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy
|
Phase 3 | |
Completed |
NCT03667859 -
Vaginal Elasticity Assessment Before and After Brachytherapy/Pelvic Radiation
|
||
Terminated |
NCT03660618 -
LSFG-SKIN, Laser Speckle Flowgraphy
|
N/A | |
Completed |
NCT00725244 -
Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias
|
Phase 4 | |
Completed |
NCT00001523 -
Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation
|
N/A | |
Recruiting |
NCT03907371 -
The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.
|
Phase 2 | |
Not yet recruiting |
NCT05063773 -
Novel Wireless Mixed Reality Headset for Image Guidance in Cardiac Catheterization Laboratory
|
N/A | |
Completed |
NCT00001437 -
Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis
|
Phase 2 | |
Recruiting |
NCT06325982 -
Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury
|
N/A | |
Completed |
NCT02972736 -
RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study
|
||
Completed |
NCT02104271 -
Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.
|
Phase 2 | |
Terminated |
NCT00134628 -
Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries
|
Phase 3 | |
Completed |
NCT03961217 -
Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes
|